Abstract
The simultaneous determination of heregulin-α and HER 1–4 plays an important role in brain cancer diagnosis and treatment. To date, only enzyme-linked immunosorbent assay (ELISA) or a semiquantitative colorimetric method have been used for the assay of these biomarkers; these methods are quite expensive and can only determine one biomarker in a run. Four 3D stochastic microsensors based on multi-walled carbon nanotubes enriched with gold nanoparticles and modified with inulin were designed for the simultaneous determination of heregulin-α and HER 1–4 in tumor brain tissue and whole blood samples. For the simultaneous measurement of HRG-α and HER 1–4, all sensors demonstrated low limits of determination (as fg mL−1 magnitude order), high sensitivities, and wide concentration ranges. From biological samples, high recovery values of more than 96% of analytes were obtained. The proposed sensor can detect HER 1–4 and heregulin-α in whole blood and tumor tissue samples at the same time.
Funder
Ministry of Research, Innovation and Digitization
Reference21 articles.
1. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the new ligand family;Falls;Cell,1993
2. Untangling the ErbB signaling network;Yarden;Nat. Rev. Mol. Cell Biol.,2001
3. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016. 388.
4. Chandra, P., Tan, Y.N., and Singh, S.P. Next Generation Point-of-Care Biomedical Sensors Technologies for Cancer Diagnosis, 2017.
5. Epidemiology and molecular pathology of glioma;Schwartzbaum;Nat. Clin. Pract. Neurol.,2006
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献